- Home
- COE vs BYSI Comparison
COE vs BYSI Comparison
Compare COE & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COE
- BYSI
- Stock Information
- Founded
- COE 2011
- BYSI 2010
- Country
- COE Singapore
- BYSI United States
- Employees
- COE N/A
- BYSI N/A
- Industry
- COE Other Consumer Services
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- COE Real Estate
- BYSI Health Care
- Exchange
- COE Nasdaq
- BYSI Nasdaq
- Market Cap
- COE 76.7M
- BYSI 68.5M
- IPO Year
- COE 2016
- BYSI 2017
- Fundamental
- Price
- COE $15.45
- BYSI $1.63
- Analyst Decision
- COE
- BYSI
- Analyst Count
- COE 0
- BYSI 0
- Target Price
- COE N/A
- BYSI N/A
- AVG Volume (30 Days)
- COE 10.3K
- BYSI 28.4K
- Earning Date
- COE 12-13-2024
- BYSI 01-01-0001
- Dividend Yield
- COE N/A
- BYSI N/A
- EPS Growth
- COE N/A
- BYSI N/A
- EPS
- COE N/A
- BYSI N/A
- Revenue
- COE $41,924,000.00
- BYSI $1,876,000.00
- Revenue This Year
- COE N/A
- BYSI N/A
- Revenue Next Year
- COE N/A
- BYSI N/A
- P/E Ratio
- COE N/A
- BYSI N/A
- Revenue Growth
- COE 69.79
- BYSI 21.03
- 52 Week Low
- COE $6.00
- BYSI $0.78
- 52 Week High
- COE $19.75
- BYSI $4.00
- Technical
- Relative Strength Index (RSI)
- COE 58.99
- BYSI 40.58
- Support Level
- COE $15.26
- BYSI $1.55
- Resistance Level
- COE $17.96
- BYSI $1.84
- Average True Range (ATR)
- COE 1.09
- BYSI 0.19
- MACD
- COE 0.33
- BYSI 0.00
- Stochastic Oscillator
- COE 68.88
- BYSI 10.96
About COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.